Bladder cancer: translating molecular genetic insights into clinical practice.
暂无分享,去创建一个
Liang Cheng | Antonio Lopez-Beltran | Rodolfo Montironi | A. Lopez‐Beltran | R. Montironi | Liang Cheng | G. MacLennan | S. Williamson | Shaobo Zhang | Shaobo Zhang | Gregory T MacLennan | Sean R Williamson | A. López-Beltran
[1] G. Netto. Molecular Pathology of Bladder Cancer. , 2012, Surgical pathology clinics.
[2] E. Zwarthoff,et al. Fibroblast growth factor receptor 3 mutations in bladder tumors correlate with low frequency of chromosome alterations. , 2008, Neoplasia.
[3] T. Ørntoft,et al. A Molecular Signature in Superficial Bladder Carcinoma Predicts Clinical Outcome , 2005, Clinical Cancer Research.
[4] N. Cho,et al. Matrix metalloproteinase expression in the recurrence of superficial low grade bladder transitional cell carcinoma. , 2007, The Journal of urology.
[5] D. Jacqmin,et al. Evaluation of microsatellite analysis in urine sediment for diagnosis of bladder cancer. , 2000, Cancer research.
[6] A Semjonow,et al. Cytogenetic analysis of multifocal bladder cancer supports a monoclonal origin and intraepithelial spread of tumor cells. , 2001, Cancer research.
[7] L. Kiemeney,et al. Prognostic value of p53 for high risk superficial bladder cancer with long-term followup. , 2007, The Journal of urology.
[8] W Lutzeyer,et al. Prognostic parameters in superficial bladder cancer: an analysis of 315 cases. , 1982, The Journal of urology.
[9] G. Steineck,et al. Epidemiology and Etiology of Premalignant and Malignant Urothelial Changes , 2000, Scandinavian journal of urology and nephrology. Supplementum.
[10] S. Lerner,et al. Role of chromosome 9 in human bladder cancer. , 1993, Cancer research.
[11] A. Tzankov,et al. Prognostic significance of tenascin-C expression in superficial and invasive bladder cancer , 2004, Journal of Clinical Pathology.
[12] F. Guadagni,et al. Genetic instability in superficial bladder cancer and adjacent mucosa: an interphase cytogenetic study. , 2003, Human pathology.
[13] J. Gu,et al. Allelic loss of the active X chromosome during bladder carcinogenesis. , 2004, Archives of pathology & laboratory medicine.
[14] Tongyu Zhu,et al. A Novel Set of DNA Methylation Markers in Urine Sediments for Sensitive/Specific Detection of Bladder Cancer , 2007, Clinical Cancer Research.
[15] S. Eissa,et al. Comparison of telomerase activity and matrix metalloproteinase-9 in voided urine and bladder wash samples as a useful diagnostic tool for bladder cancer. , 2003, European urology.
[16] D. Makarov,et al. Nucleic acid-based marker approaches to urologic cancers. , 2006, Urologic oncology.
[17] L. Frati,et al. A chemosensitivity test to individualize intravesical treatment for non‐muscle‐invasive bladder cancer , 2009, BJU international.
[18] W. Schulze,et al. Analysis of genetic alterations in normal bladder urothelium. , 2003, Urology.
[19] Yair Lotan,et al. Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy , 2008, Cancer.
[20] I. Gkialas,et al. Evaluation of urine tumor-associated trypsin inhibitor, CYFRA 21-1, and urinary bladder cancer antigen for detection of high-grade bladder carcinoma. , 2008, Urology.
[21] A Hofstetter,et al. Frequent genetic alterations in simple urothelial hyperplasias of the bladder in patients with papillary urothelial carcinoma. , 1999, The American journal of pathology.
[22] A. Pycha,et al. Multiprobe fluorescence in situ hybridisation: prognostic perspectives in superficial bladder cancer , 2006, Journal of Clinical Pathology.
[23] Y. Lotan,et al. Ki-67 Is an Independent Predictor of Bladder Cancer Outcome in Patients Treated with Radical Cystectomy for Organ-Confined Disease , 2006, Clinical Cancer Research.
[24] R. Takahashi,et al. Metachronous multifocal development of urothelial cancers by intraluminal seeding , 1993, The Lancet.
[25] E. Higashihara,et al. Detection of circulating MUC7‐positive cells by reverse transcription–polymerase chain reaction in bladder cancer patients , 2004, International journal of urology : official journal of the Japanese Urological Association.
[26] F. Burkhard,et al. Radical cystectomy for bladder cancer today--a homogeneous series without neoadjuvant therapy. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] Peter A. Jones,et al. Mechanisms of Disease: genetic and epigenetic alterations that drive bladder cancer , 2005, Nature Clinical Practice Urology.
[28] N. Malats,et al. FGFR3 and Tp53 Mutations in T1G3 Transitional Bladder Carcinomas: Independent Distribution and Lack of Association with Prognosis , 2005, Clinical Cancer Research.
[29] M. Burset,et al. Molecular lymph node staging in bladder urothelial carcinoma: impact on survival. , 2008, European urology.
[30] Anirban P. Mitra,et al. Molecular markers in bladder cancer , 2008, Current opinion in urology.
[31] Eun-Jung Kim,et al. RUNX3 inactivation by point mutations and aberrant DNA methylation in bladder tumors. , 2005, Cancer research.
[32] D. Parkin,et al. The global burden of urinary bladder cancer , 2008, Scandinavian journal of urology and nephrology. Supplementum.
[33] P. Jones,et al. DNA methylation errors and cancer. , 1996, Cancer research.
[34] M. Stöckle,et al. Detection of occult tumor cells in lymph nodes from bladder cancer patients by MUC7 nested RT-PCR. , 2004, European urology.
[35] S. Shariat,et al. Bladder cancer: Nomogram aids clinical decision making after radical cystectomy , 2010, Nature Reviews Urology.
[36] L. Koss,et al. Mapping cancerous and precancerous bladder changes. A study of the urothelium in ten surgically removed bladders. , 1974, JAMA.
[37] G. de Rosa,et al. Role of Polysomy 17 in Transitional Cell Carcinoma of the Bladder: Immunohistochemical Study of HER2/neu Expression and FISH Analysis of c-erbB-2 Gene and Chromosome 17 , 2009, International journal of surgical pathology.
[38] Carsten Wiuf,et al. Role of Activating Fibroblast Growth Factor Receptor 3 Mutations in the Development of Bladder Tumors , 2005, Clinical Cancer Research.
[39] A. Shalhav,et al. The predictive value of multi-targeted fluorescent in-situ hybridization in patients with history of bladder cancer. , 2008, Urologic oncology.
[40] T. H. van der Kwast,et al. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] T. H. van der Kwast,et al. Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study. , 2008, European urology.
[42] W. Shipley,et al. Bladder cancer , 2009, The Lancet.
[43] M. Babjuk,et al. Analysis of genetic events in 17p13 and 9p21 regions supports predominant monoclonal origin of multifocal and recurrent bladder cancer. , 2006, Cancer Letters.
[44] M. Milowsky,et al. Detection of circulating tumor cells in patients with urothelial cancer. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[45] R. Millikan,et al. Focus on bladder cancer. , 2004, Cancer cell.
[46] J. Chang,et al. Bladder Cancer Initiating Cells (BCICs) Are Among EMA−CD44v6+ Subset: Novel Methods for Isolating Undetermined Cancer Stem (Initiating) Cells , 2008, Cancer investigation.
[47] R. Montironi,et al. Chromosomal abnormalities in macroscopically normal urothelium in patients with bladder pT1 and pT2a urothelial carcinoma: a fluorescence in situ hybridization study and correlation with histologic features. , 2005, Analytical and quantitative cytology and histology.
[48] Å. Borg,et al. MiRNA expression in urothelial carcinomas: Important roles of miR‐10a, miR‐222, miR‐125b, miR‐7 and miR‐452 for tumor stage and metastasis, and frequent homozygous losses of miR‐31 , 2009, International journal of cancer.
[49] R. Knuechel,et al. Occurrence of chromosome 9 and p53 alterations in multifocal dysplasia and carcinoma in situ of human urinary bladder. , 2002, Cancer research.
[50] Liang Cheng,et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. , 2005, Urology.
[51] Howard Y. Chang,et al. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells , 2009, Proceedings of the National Academy of Sciences.
[52] R. Dahiya,et al. Combination analysis of hypermethylated Wnt-antagonist family genes as a novel epigenetic biomarker panel for bladder cancer detection. , 2007, Clinical cancer research : an official journal of the American Association for Cancer Research.
[53] K. Husgafvel‐Pursiainen,et al. Promoter Hypermethylation in Tumour Suppressor Genes Shows Association with Stage, Grade and Invasiveness of Bladder Cancer , 2008, Oncology.
[54] C. Roehrborn,et al. Variability in the performance of nuclear matrix protein 22 for the detection of bladder cancer. , 2006, The Journal of urology.
[55] C. R. Leemans,et al. A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications. , 2003, Cancer research.
[56] J. Gu,et al. Precise microdissection of human bladder carcinomas reveals divergent tumor subclones in the same tumor , 2002, Cancer.
[57] Yue Zhang,et al. The Implications of Cancer Stem Cells for Cancer Therapy , 2012, International journal of molecular sciences.
[58] Carlos Cordon-Cardo,et al. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[59] Mogens Kruhøffer,et al. Gene Expression in the Urinary Bladder , 2004, Cancer Research.
[60] V. Lokeshwar,et al. Potential new urinary markers in the early detection of bladder cancer , 2009, Current opinion in urology.
[61] S. Goodison,et al. Urinary proteomic profiling for diagnostic bladder cancer biomarkers , 2009, Expert review of proteomics.
[62] E. Messing,et al. Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. , 2005, Urology.
[63] R. Paterson,et al. Molecular genetic alterations in the laser‐capture–microdissected stroma adjacent to bladder carcinoma , 2003, Cancer.
[64] F. Boccardo,et al. Differential Proteomic Analysis of Nuclear Matrix in Muscle-Invasive Bladder Cancer: Potential to Improve Diagnosis and Prognosis , 2008, Cellular oncology : the official journal of the International Society for Cellular Oncology.
[65] S. Lenk,et al. TP53 gene mutations as an independent marker for urinary bladder cancer progression. , 2008, International journal of molecular medicine.
[66] N. Malats,et al. P53 as a prognostic marker for bladder cancer: a meta-analysis and review. , 2005, The Lancet. Oncology.
[67] T. Furuya,et al. 9p21 index as estimated by dual-color fluorescence in situ hybridization is useful to predict urothelial carcinoma recurrence in bladder washing cytology. , 2009, Human pathology.
[68] Xue-Ru Wu. Urothelial tumorigenesis: a tale of divergent pathways , 2005, Nature Reviews Cancer.
[69] M. Babjuk,et al. Urinary cytology and quantitative BTA and UBC tests in surveillance of patients with pTapT1 bladder urothelial carcinoma. , 2008, Urology.
[70] Yair Lotan,et al. Nomograms Provide Improved Accuracy for Predicting Survival after Radical Cystectomy , 2006, Clinical Cancer Research.
[71] P. Tan,et al. TP53 mutational analysis supports monoclonal origin of biphasic sarcomatoid urothelial carcinoma (carcinosarcoma) of the urinary bladder , 2009, Modern Pathology.
[72] J. Chin,et al. Prospective evaluation of the prognostic relevance of molecular staging for urothelial carcinoma , 2006, Cancer.
[73] R. Cote,et al. Two molecular pathways to transitional cell carcinoma of the bladder. , 1994, Cancer research.
[74] Anne-Mette K. Hein,et al. Gene Expression Signatures Predict Outcome in Non–Muscle-Invasive Bladder Carcinoma: A Multicenter Validation Study , 2007, Clinical Cancer Research.
[75] Paul R Young,et al. Bladder Cancer–Associated Gene Expression Signatures Identified by Profiling of Exfoliated Urothelia , 2009, Cancer Epidemiology Biomarkers & Prevention.
[76] P. Laird,et al. Promoter hypermethylation: a new therapeutic target emerges in urothelial cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[77] Yuanqing Ye,et al. Evaluation of genetic variants in microRNA-related genes and risk of bladder cancer. , 2008, Cancer research.
[78] M. Becich,et al. Clonal analysis of human recurrent superficial bladder cancer by immunohistochemistry of P53 and retinoblastoma proteins. , 1996, The Journal of urology.
[79] M. Droller. FGFR3 and P53 Characterize Alternative Genetic Pathways in the Pathogenesis of Urothelial Cell Carcinoma , 2004 .
[80] C. Dinney,et al. Molecular markers of urothelial cancer and their use in the monitoring of superficial urothelial cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[81] M. Babjuk,et al. Molecular cytogenetic characterization and diagnostics of bladder cancer. , 2007, Neoplasma.
[82] M. Zeegers,et al. The association between smoking, beverage consumption, diet and bladder cancer: a systematic literature review , 2003, World Journal of Urology.
[83] Y. Lotan,et al. Survivin expression is associated with bladder cancer presence, stage, progression, and mortality. , 2006, Cancer.
[84] Wentian Li,et al. Copyright © American Society for Investigative Pathology Gene Discovery in Bladder Cancer Progression using cDNA Microarrays , 2022 .
[85] M. Jaye,et al. Fibroblast growth factor receptor tyrosine kinases: molecular analysis and signal transduction. , 1992, Biochimica et biophysica acta.
[86] M. Kattan,et al. Predicting Nonsentinel Node Status After Positive Sentinel Lymph Biopsy for Breast Cancer: Clinicians Versus Nomogram , 2005, Annals of Surgical Oncology.
[87] A. N. Meyer,et al. Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4 , 2000, Oncogene.
[88] R. Simon,et al. Patterns of chromosomal imbalances in muscle invasive bladder cancer. , 2000, International journal of oncology.
[89] D. Neal,et al. Expression of retinoblastoma gene product and p53 protein in bladder carcinoma: correlation with Ki67 index. , 1995, British journal of urology.
[90] M. Droller. Grading and staging of bladder carcinoma in transurethral resection specimens: correlation with 105 matched cystectomy specimens. , 2000, The Journal of urology.
[91] M. Naoe,et al. Detection of circulating urothelial cancer cells in the blood using the CellSearch System , 2007, Cancer.
[92] N. Kinukawa,et al. p53 mutations in multiple urothelial carcinomas: a molecular analysis of the development of multiple carcinomas. , 1997, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[93] O. Hakenberg,et al. Comparative diagnostic value of urine cytology, UBC-ELISA, and fluorescence in situ hybridization for detection of transitional cell carcinoma of urinary bladder in routine clinical practice. , 2007, Urology.
[94] U. Michl,et al. Immunocyt and the HA-HAase urine tests for the detection of bladder cancer: a side-by-side comparison. , 2004, European urology.
[95] I. Sesterhenn,et al. World health organization classifications of tumours. pathology and genetics of tumours of the urinary system and male genital organs , 2005 .
[96] J. García Rodríguez,et al. Urinary CYFRA 21.1 is not a useful marker for the detection of recurrences in the follow-up of superficial bladder cancer. , 2007, European urology.
[97] B. Vogelstein,et al. Clonal origin of bladder cancer. , 1992, The New England journal of medicine.
[98] W. Gianni,et al. Detection of epidermal growth factor receptor mRNA in peripheral blood: a new marker of circulating neoplastic cells in bladder cancer patients. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[99] Christian Pilarsky,et al. Gene Expression Profiling of Progressive Papillary Noninvasive Carcinomas of the Urinary Bladder , 2005, Clinical Cancer Research.
[100] M. Knowles,et al. FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer , 2007, The Journal of pathology.
[101] L. Bubendorf,et al. Multiprobe FISH for enhanced detection of bladder cancer in voided urine specimens and bladder washings. , 2001, American journal of clinical pathology.
[102] F. Hamdy,et al. FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours. , 2009, European urology.
[103] Ewout W Steyerberg,et al. Microsatellite analysis of voided-urine samples for surveillance of low-grade non-muscle-invasive urothelial carcinoma: feasibility and clinical utility in a prospective multicenter study (Cost-Effectiveness of Follow-Up of Urinary Bladder Cancer trial [CEFUB]). , 2009, European urology.
[104] Keishi Yamashita,et al. High-throughput molecular analysis of urine sediment for the detection of bladder cancer by high-density single-nucleotide polymorphism array. , 2003, Cancer research.
[105] N. Malats,et al. Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[106] M. Schwartz,et al. Under-representation of bladder transitional cell tumour 9q, 11p and 14q LOH in urine and impact on molecular diagnosis. , 2005, Anticancer research.
[107] M. Kattan. Nomograms. Introduction. , 2002, Seminars in urologic oncology.
[108] H. Huland,et al. A side by side comparison of cytology and biomarkers for bladder cancer detection. , 2004, The Journal of urology.
[109] Wun-Jae Kim,et al. Epigenetic biomarkers in urothelial bladder cancer , 2009, Expert review of molecular diagnostics.
[110] R. Knuechel,et al. Clonality of multifocal urothelial carcinomas: 10 years of molecular genetic studies , 2002, International journal of cancer.
[111] R. Oyasu,et al. World Health Organization and International Society of Urological Pathology classification and two‐number grading system of bladder tumors , 2000, Cancer.
[112] D. Rimoin,et al. Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3 , 1995, Nature Genetics.
[113] A. Marx,et al. World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of the Urinary System and Male Genital Organs , 2004 .
[114] T. H. van der Kwast,et al. Combined microsatellite and FGFR3 mutation analysis enables a highly sensitive detection of urothelial cell carcinoma in voided urine. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[115] H. Mischak,et al. Proteomics in Gerontology: Current Applications and Future Aspects – A Mini-Review , 2009, Gerontology.
[116] H. Miyake,et al. Detection of Micrometastases in Pelvic Lymph Nodes in Patients Undergoing Radical Cystectomy for Focally Invasive Bladder Cancer by Real-time Reverse Transcriptase-PCR for Cytokeratin 19 and Uroplakin II , 2005, Clinical Cancer Research.
[117] T. Habuchi,et al. Distinct microsatellite alterations in upper urinary tract tumors and subsequent bladder tumors. , 2001, The Journal of urology.
[118] A. Tzankov,et al. Large-Scale Analysis of Cell Cycle Regulators in Urothelial Bladder Cancer Identifies p16 and p27 as Potentially Useful Prognostic Markers , 2008, Pathobiology.
[119] Liang Cheng,et al. Clonal origin of lymph node metastases in bladder carcinoma , 2005, Cancer.
[120] Y. Soini,et al. the urinary bladder correlates with disease progression , 2022 .
[121] M. Swellam,et al. Detection of telomerase in urine by 3 methods: evaluation of diagnostic accuracy for bladder cancer. , 2007, The Journal of urology.
[122] Ronald Simon,et al. Bladder Cancer-associated Protein, a Potential Prognostic Biomarker in Human Bladder Cancer* , 2009, Molecular & Cellular Proteomics.
[123] Liang Cheng,et al. Molecular Evidence Supporting Field Effect in Urothelial Carcinogenesis , 2005, Clinical Cancer Research.
[124] Joel S Parker,et al. Extensive post-transcriptional regulation of microRNAs and its implications for cancer. , 2006, Genes & development.
[125] T. Sun,et al. Detection of circulating uroplakin-positive cells in patients with transitional cell carcinoma of the bladder. , 1999, The Journal of urology.
[126] Rolf Ackermann,et al. Identifying Superficial, Muscle-Invasive, and Metastasizing Transitional Cell Carcinoma of the Bladder , 2004, Clinical Cancer Research.
[127] M. Wirth,et al. Detection of Bladder Cancer Using a Point-of-Care Proteomic Assay , 2006 .
[128] R. Montironi,et al. Frequent FGFR3 mutations in urothelial papilloma , 2002, The Journal of pathology.
[129] Paul Cairns,et al. Genome-wide genetic characterization of bladder cancer: a comparison of high-density single-nucleotide polymorphism arrays and PCR-based microsatellite analysis. , 2003, Cancer research.
[130] J. Ferlay,et al. Globocan 2000 : cancer incidence, mortality and prevalence worldwide , 2001 .
[131] A. Regev,et al. An embryonic stem cell–like gene expression signature in poorly differentiated aggressive human tumors , 2008, Nature Genetics.
[132] M. Knowles,et al. Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer , 2007, Oncogene.
[133] A. Pycha,et al. uCyt+/ImmunoCyt™ in the detection of recurrent urothelial carcinoma , 2006, Cancer.
[134] R. Knuechel,et al. Oligoclonality of Early Lesions of the Urothelium as Determined by Microdissection-Supported Genetic Analysis , 2001, Pathobiology.
[135] Ryan P. McCarthy,et al. Molecular genetic evidence for a common clonal origin of urinary bladder small cell carcinoma and coexisting urothelial carcinoma. , 2005, The American journal of pathology.
[136] B. Têtu,et al. Diagnosis of urothelial carcinoma from urine , 2009, Modern Pathology.
[137] D. Pode,et al. Evaluation of urine CYFRA 21‐1 for the detection of primary and recurrent bladder carcinoma , 2002, Cancer.
[138] Minyou Chen,et al. Artificial intelligence in predicting bladder cancer outcome: a comparison of neuro-fuzzy modeling and artificial neural networks. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[139] Jane Fridlyand,et al. Bladder Cancer Stage and Outcome by Array-Based Comparative Genomic Hybridization , 2005, Clinical Cancer Research.
[140] Liang Cheng,et al. "Field cancerization" in the urothelium of the bladder. , 2006, Analytical and quantitative cytology and histology.
[141] L. Cannizzaro,et al. Identical clonal origin of synchronous and metachronous low-grade, noninvasive papillary transitional cell carcinomas of the urinary tract. , 1999, Human pathology.
[142] J. Oxley,et al. Preoperative p53, bcl-2, CD44 and E-cadherin immunohistochemistry as predictors of biochemical relapse after radical prostatectomy. , 1999, The Journal of urology.
[143] A. Jemal,et al. Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.
[144] D. Polsky,et al. Detection of circulating cancer cells expressing uroplakins and epidermal growth factor receptor in bladder cancer patients , 2004, International journal of cancer.
[145] D. Donoghue,et al. Enhanced signaling and morphological transformation by a membrane-localized derivative of the fibroblast growth factor receptor 3 kinase domain , 1997, Molecular and cellular biology.
[146] Jørgen Kjems,et al. Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro. , 2009, Cancer research.
[147] S. Shariat,et al. Stage specific lymph node metastasis mapping in radical cystectomy specimens. , 2004, The Journal of urology.
[148] Anirban P. Mitra,et al. The use of genetic programming in the analysis of quantitative gene expression profiles for identification of nodal status in bladder cancer , 2006, BMC Cancer.
[149] T. Frebourg,et al. Molecular profiling of bladder tumors based on the detection of FGFR3 and TP53 mutations. , 2006, The Journal of urology.
[150] R. Montironi,et al. Loss of heterozygosity at 9q32–33 (DBC1 locus) in primary non‐invasive papillary urothelial neoplasm of low malignant potential and low‐grade urothelial carcinoma of the bladder and their associated normal urothelium , 2008, The Journal of pathology.
[151] J. Gu,et al. High-order interactions among genetic polymorphisms in nucleotide excision repair pathway genes and smoking in modulating bladder cancer risk. , 2007, Carcinogenesis.
[152] S. Devries,et al. Identification of gains and losses of DNA sequences in primary bladder cancer by comparative genomic hybridization , 1995, Genes, chromosomes & cancer.
[153] G. Nesi,et al. Loss of P16 expression and chromosome 9p21 LOH in predicting outcome of patients affected by superficial bladder cancer. , 2007, The Journal of surgical research.
[154] Yair Lotan,et al. Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder. , 2006, The Journal of urology.
[155] A. Tasdemir,et al. Significantly Increased Accuracy of Urothelial Carcinoma Detection in Destained Urine Slides with Combined Analysis of Standard Cytology and CK-20 Immunostainıng , 2009, Acta Cytologica.
[156] A. Sagalowsky,et al. The use of histone deacetylase inhibitor FK228 and DNA hypomethylation agent 5‐azacytidine in human bladder cancer therapy , 2007, International journal of cancer.
[157] I. N. Reid,et al. Molecular screening of multifocal transitional cell carcinoma of the bladder using p53 mutations as biomarkers. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.
[158] R. Montironi,et al. Molecular pathogenesis of urothelial carcinoma: the clinical utility of emerging new biomarkers and future molecular classification of bladder cancer. , 2009, Analytical and quantitative cytology and histology.
[159] P. Tamboli,et al. Plasmacytoid Urothelial Carcinoma: Detailed Analysis of Morphology With Clinicopathologic Correlation in 17 Cases , 2009, The American journal of surgical pathology.
[160] S. Rosengren,et al. Distinct missense mutations of the FGFR3 lys650 codon modulate receptor kinase activation and the severity of the skeletal dysplasia phenotype. , 2000, American journal of human genetics.
[161] O. Patschan,et al. Combinations of urine-based tumour markers in bladder cancer surveillance , 2009, Scandinavian journal of urology and nephrology.
[162] Yu Zeng,et al. Uroplakin II as a promising marker for molecular diagnosis of nodal metastases from bladder cancer: comparison with cytokeratin 20. , 2005, The Journal of urology.
[163] D. Chopin,et al. Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b. , 2006, Carcinogenesis.
[164] Anirban P. Mitra,et al. Predicting recurrence and progression of noninvasive papillary bladder cancer at initial presentation based on quantitative gene expression profiles. , 2010, European urology.
[165] E. Higashihara,et al. Detection of mucin 7 gene expression in exfoliated cells in urine from patients with bladder tumor. , 2003, Urology.
[166] T. H. van der Kwast,et al. The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. , 2001, Cancer research.
[167] W. M. Linehan,et al. Unexplained excess risk of bladder cancer in men. , 1990, Journal of the National Cancer Institute.
[168] M. Noble,et al. Cancer stem cells. , 2006, The New England journal of medicine.
[169] D. Spandidos,et al. Activation of RAS family genes in urothelial carcinoma. , 2009, The Journal of urology.
[170] R. Weinstein. Origin and dissemination of human urinary bladder carcinoma. , 1979, Seminars in oncology.
[171] L. Kiemeney,et al. Predictability of recurrent and progressive disease in individual patients with primary superficial bladder cancer. , 1993, The Journal of urology.
[172] Torben F. Ørntoft,et al. Identifying distinct classes of bladder carcinoma using microarrays , 2003, Nature Genetics.
[173] A. Lopez‐Beltran,et al. Molecular determinants of tumor recurrence in the urinary bladder. , 2009, Future oncology.
[174] Yusuke Nakamura,et al. Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.
[175] P. Schellhammer,et al. Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. , 2002, The Journal of urology.
[176] S. Kagawa,et al. Prognostic value of Ki-67 antigen and p53 protein in urinary bladder cancer: immunohistochemical analysis of radical cystectomy specimens. , 1997, British journal of urology.
[177] M. Kattan. Prostate cancer nomograms and prognostic models: Introduction , 2002 .
[178] I. Mills,et al. Comprehensive profiling and localisation of the matrix metalloproteinases in urothelial carcinoma , 2006, British Journal of Cancer.
[179] K. Iczkowski,et al. Divergent differentiation in urothelial carcinoma and other bladder cancer subtypes with selected mimics , 2009, Histopathology.
[180] P. Carroll,et al. A multicolour fluorescence in situ hybridization test predicts recurrence in patients with high‐risk superficial bladder tumours undergoing intravesical therapy , 2009, BJU international.
[181] O. Yoshida,et al. Clonal and chronological genetic analysis of multifocal cancers of the bladder and upper urinary tract. , 1998, Cancer research.
[182] M. Srougi,et al. Testing for urinary hyaluronate improves detection and grading of transitional cell carcinoma. , 2011, Urologic oncology.
[183] A. Akdaş,et al. Nuclear accumulation of mutant p53 protein: a possible predictor of failure of intravesical therapy in bladder cancer. , 1997, British journal of urology.
[184] Dirk Zaak,et al. Clonality and Genetic Divergence in Multifocal Low-Grade Superficial Urothelial Carcinoma as Determined by Chromosome 9 and p53 Deletion Analysis , 2000, Laboratory Investigation.
[185] A. Longatto-Filho,et al. The aggressiveness of urothelial carcinoma depends to a large extent on lymphovascular invasion – the prognostic contribution of related molecular markers , 2009, Histopathology.
[186] Y. Lotan,et al. Prospective validation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder. , 2008, The Journal of urology.
[187] J. Chin,et al. Molecular determination of perivesical and lymph node metastasis after radical cystectomy for urothelial carcinoma of the bladder. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[188] L. N. Pogozheva. [Neoplasms of the urinary bladder]. , 1967, Meditsinskaia sestra.
[189] T. Tuschl,et al. Identification of Novel Genes Coding for Small Expressed RNAs , 2001, Science.
[190] Y. Lotan,et al. Association of angiogenesis related markers with bladder cancer outcomes and other molecular markers. , 2010, The Journal of urology.
[191] J. Cheville,et al. Flat intraepithelial lesions of the urinary bladder , 2000, Cancer.
[192] P. Carroll,et al. The impact of lymphadenectomy and lymph node metastasis on the outcomes of radical cystectomy for bladder cancer. , 2009, European urology.
[193] J. Cheville,et al. Evidence for oligoclonality and tumor spread by intraluminal seeding in multifocal urothelial carcinomas of the upper and lower urinary tract , 2001, Oncogene.
[194] D. Bostwick,et al. World Health Organization and International Society of Urological Pathology classification and Two‐number grading system of bladder tumors , 2000, Cancer.
[195] Torben F. Ørntoft,et al. Emmprin and Survivin Predict Response and Survival following Cisplatin-Containing Chemotherapy in Patients with Advanced Bladder Cancer , 2007, Clinical Cancer Research.
[196] C. Abbou,et al. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. , 2001, The American journal of pathology.
[197] G. Schaefer,et al. Chromosomal aberrations in urothelial carcinoma of the bladder and the World Health Organization 2004 grading system. , 2008, Analytical and quantitative cytology and histology.
[198] Wen-Jeng Wu,et al. Increase sensitivity in detecting superficial, low grade bladder cancer by combination analysis of hypermethylation of E-cadherin, p16, p14, RASSF1A genes in urine. , 2010, Urologic oncology.
[199] N. Shimizu,et al. p53 gene mutation in recurrent superficial bladder cancer. , 1995, The Journal of urology.
[200] Yusuke Nakamura,et al. Validation study of the prediction system for clinical response of M‐VAC neoadjuvant chemotherapy , 2007, Cancer science.
[201] M. Knowles. Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target , 2007, World Journal of Urology.
[202] T. Kwast,et al. Urine markers for bladder cancer surveillance: a systematic review. , 2005 .
[203] Anirban P. Mitra,et al. Generation of a concise gene panel for outcome prediction in urinary bladder cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[204] H. Wallerand,et al. Mutations in TP53, but not FGFR3, in urothelial cell carcinoma of the bladder are influenced by smoking: contribution of exogenous versus endogenous carcinogens. , 2004, Carcinogenesis.
[205] M. Walsh,et al. Immunohistological expression of p53 in primary pT1 transitional cell bladder cancer in relation to tumour progression. , 1994, British journal of urology.
[206] Ekaterini Blaveri,et al. Bladder cancer outcome and subtype classification by gene expression. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.
[207] P. Tan,et al. Histogenesis of Clear Cell Adenocarcinoma in the Urinary Tract: Evidence of Urothelial Origin , 2008, Clinical Cancer Research.
[208] R. Montironi,et al. Morphological and molecular profiles and pathways in bladder neoplasms. , 2008, Anticancer research.
[209] D. Hanahan,et al. The Hallmarks of Cancer , 2000, Cell.
[210] MULTI-INSTITUTIONAL VALIDATION OF THE PREDICTIVE VALUE OF KI-67 LABELING INDEX IN PATIENTS WITH URINARY BLADDER CANCER , 2009 .
[211] M. Burset,et al. DNA microarray expression profiling of bladder cancer allows identification of noninvasive diagnostic markers. , 2009, The Journal of urology.
[212] K. Baggerly,et al. High-resolution whole-organ mapping with SNPs and its significance to early events of carcinogenesis , 2005, Laboratory Investigation.
[213] I. Petersen,et al. p53 mutations in phenacetin-associated human urothelial carcinomas. , 1993, Carcinogenesis.
[214] F. Liedberg,et al. The value of the UroVysion assay for surveillance of non-muscle-invasive bladder cancer. , 2008, European urology.
[215] Wun-Jae Kim,et al. Requirement for Ras/Raf/ERK pathway in naringin-induced G1-cell-cycle arrest via p21WAF1 expression. , 2008, Carcinogenesis.
[216] Saiful Miah,et al. Distinct microRNA alterations characterize high- and low-grade bladder cancer. , 2009, Cancer research.
[217] P. Tan,et al. Histogenesis of sarcomatoid urothelial carcinoma of the urinary bladder: evidence for a common clonal origin with divergent differentiation , 2007, The Journal of pathology.
[218] R. Knuechel,et al. Value of multicolour fluorescence in situ hybridisation (UroVysion) in the differential diagnosis of flat urothelial lesions , 2007, Journal of Clinical Pathology.
[219] J. Witjes,et al. UroVysion compared with cytology and quantitative cytology in the surveillance of non-muscle-invasive bladder cancer. , 2007, European urology.
[220] Adel H Jebar,et al. FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma , 2005, Oncogene.
[221] Wun-Jae Kim,et al. Epigenetic markers as promising prognosticators for bladder cancer , 2009, International journal of urology : official journal of the Japanese Urological Association.
[222] Balraj Mittal,et al. Microsatellite instability as prognostic marker in bladder tumors: a clinical significance , 2005, BMC urology.
[223] Yair Lotan,et al. Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder. , 2005, The Journal of urology.
[224] L. Sokoll,et al. The presence of circulating tumor cells does not predict extravesical disease in bladder cancer patients prior to radical cystectomy. , 2012, Urologic oncology.
[225] S. Cross,et al. Promoter Hypermethylation Identifies Progression Risk in Bladder Cancer , 2007, Clinical Cancer Research.
[226] T. Ebert,et al. Immunocytology in the assessment of patients with painless gross haematuria , 2007, BJU international.
[227] Ishtiaq Rehman,et al. Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[228] H. Wallerand,et al. FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. , 2003, Cancer research.
[229] J. Cheville,et al. A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in urine. , 2002, The Journal of urology.
[230] M. Terris,et al. The use of Urovysion™ fluorescence in situ hybridization in the diagnosis and surveillance of non-urothelial carcinoma of the bladder , 2009, Modern Pathology.
[231] H. Nishiyama,et al. P21-activated kinase 1: a new molecular marker for intravesical recurrence after transurethral resection of bladder cancer. , 2007, The Journal of urology.
[232] J. Cheville,et al. Natural history of urothelial dysplasia of the bladder. , 1999, The American journal of surgical pathology.
[233] P. Jones,et al. Altered DNA methylation and genome instability: a new pathway to cancer? , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[234] William A. See,et al. Surveillance for recurrent bladder cancer using a point-of-care proteomic assay , 2006 .
[235] K. Grigor,et al. Loss of heterozygosity on chromosomes 11 and 17 are markers of recurrence in TCC of the bladder , 2001, British Journal of Cancer.
[236] M. Soloway,et al. Current bladder tumor tests: does their projected utility fulfill clinical necessity? , 2001, The Journal of urology.
[237] G. Tsujimoto,et al. Secreted CXCL1 Is a Potential Mediator and Marker of the Tumor Invasion of Bladder Cancer , 2008, Clinical Cancer Research.
[238] D J O'Kane,et al. A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma. , 2000, The Journal of urology.
[239] M. Droller,et al. Bladder cancer: State‐of‐the‐art care , 1998, CA: a cancer journal for clinicians.
[240] Hideyasu Matsuyama,et al. Biological Characteristics in Bladder Cancer Depend on the Type of Genetic Instability , 2006, Clinical Cancer Research.
[241] S. Hautmann,et al. Bladder tumor markers for monitoring recurrence and screening comparison of hyaluronic acid–hyaluronidase and BTA‐Stat tests , 2002, Cancer.
[242] T. Ørntoft,et al. Gene expression profiling of noninvasive primary urothelial tumours using microarrays , 2005, British Journal of Cancer.
[243] D. Chopin,et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas , 1999, Nature Genetics.
[244] R. Dahse,et al. P53 mutations as an identification marker for the clonal origin of bladder tumors and its recurrences. , 2003, Oncology reports.
[245] K. To,et al. Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[246] L. Kiemeney,et al. Gene expression analysis for the prediction of recurrence in patients with primary Ta urothelial cell carcinoma. , 2007, European urology.
[247] R. Knuechel,et al. Frequent genetic alterations in flat urothelial hyperplasias and concomitant papillary bladder cancer as detected by CGH, LOH, and FISH analyses , 2003, The Journal of pathology.
[248] Chin-Lee Wu,et al. Cystatin B As a Tissue and Urinary Biomarker of Bladder Cancer Recurrence and Disease Progression , 2009, Clinical Cancer Research.
[249] Å. Borg,et al. Molecular characterization of early-stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q , 2006, Oncogene.
[250] A. Chapelle. Testing tumors for microsatellite instability , 1999, European Journal of Human Genetics.
[251] Y. Lotan,et al. Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma. , 2007, The Journal of urology.
[252] F. Mitelman,et al. Cytogenetic monoclonality in multifocal uroepithelial carcinomas: evidence of intraluminal tumour seeding , 1999, British Journal of Cancer.